rs2228000 — XPC Ala499Val

Every day your cells cope with thousands of DNA lesions — from ultraviolet light, environmental carcinogens, and byproducts of normal cellular metabolism. The XPC protein is the first responder in the global-genome nucleotide excision repair pathway¹¹ global-genome nucleotide excision repair pathway
GG-NER scans the entire genome for bulky DNA lesions, including UV-induced cyclobutane pyrimidine dimers and carcinogen-DNA adducts. XPC recognizes structural distortions in DNA caused by such lesions and recruits downstream repair factors. Without efficient XPC function, damaged nucleotides persist longer before repair initiates, increasing the chance that replication across the lesion introduces a permanent mutation.

The rs2228000 variant (Ala499Val, described as C>T in older literature using coding-strand notation) lies at codon 499 of the XPC open reading frame. The ancestral Ala499 allele (G on the plus strand, ~75% globally) encodes the efficient repair form. The derived Val499 allele (A on the plus strand, ~25% globally) substitutes a nonpolar valine for alanine at a position within XPC's central domain, subtly altering local protein structure and reducing damage recognition efficiency. This SNP complements the well-studied rs2228001 (Lys939Gln) in the same gene, and the two are in partial linkage disequilibrium — together they provide a more complete picture of XPC function than either variant alone.

XPC's central domain mediates binding to the distorted minor groove of damaged DNA and facilitates loading of the downstream TFIIH helicase complex. Codon 499 sits within a region implicated in DNA substrate binding²² Codon 499 sits within a region implicated in DNA substrate binding
Structural analyses of the XPC-RAD23B complex show that the central domain contacts the undamaged strand opposite the lesion; substitutions in this region reduce the affinity and kinetics of damage recognition without abolishing it entirely. The Ala-to-Val substitution introduces a slightly larger side chain, which may modestly alter the binding geometry. Ex vivo host-cell reactivation assays show that Val499 carriers have measurably reduced DNA repair capacity compared to Ala499 homozygotes, and the effect is dose-dependent: heterozygotes have intermediate repair activity, while Val/Val homozygotes show the most pronounced deficit.

Unlike the Lys939Gln variant (rs2228001), which maps to the C-terminal TFIIH-interaction domain, Ala499Val operates at the DNA substrate binding step. These two functional domains are distinct, so compound carriers of risk alleles at both positions could face compounded impairment at sequential steps in the NER initiation sequence.

The largest analysis of rs2228000 to date is a comprehensive meta-analysis of 71 studies³³ comprehensive meta-analysis of 71 studies
Liu et al. Biosci Rep 2019 — 26,835 cancer cases and 37,069 controls across multiple cancer types. For bladder cancer, homozygous Val/Val carriers (plus-strand AA) showed 68% higher risk compared to Ala/Ala carriers (TT vs CC: OR=1.68, 95% CI 1.25–2.26, p=0.001), and even the T allele in aggregate conferred measurable risk (T vs C: OR=1.25, CI 1.07–1.45). For breast cancer, Val/Val homozygotes had 33% higher risk (TT vs CC: OR=1.33, CI 1.10–1.60, p=0.003). Across all 71 studies combined, the homozygous recessive comparison reached significance (TT vs CC+CT: OR=1.11, CI 1.01–1.22).

An earlier meta-analysis of 34 studies⁴⁴ meta-analysis of 34 studies
He et al. Int J Cancer 2013 — 14,877 cases and 17,888 controls found 21% higher overall cancer risk for Val/Val vs Ala/Ala (OR=1.21, 95% CI 1.07–1.36, p=0.003) with the strongest effects in breast and bladder cancer and in Asian study populations. The recessive model OR was essentially identical (OR=1.20, CI 1.08–1.34, p=0.001), indicating the risk is concentrated in homozygous carriers rather than being evenly distributed across heterozygotes.

Bladder cancer has emerged as the most robustly associated malignancy. A dedicated bladder cancer study and meta-analysis⁵⁵ dedicated bladder cancer study and meta-analysis
Rashed et al. Mutat Res 2016 — 234 cases and 258 controls, plus pooled meta-analysis of 7 studies (2,893 cases / 3,056 controls) confirmed that the Val allele is an independent bladder cancer risk factor (OR=1.54, CI 1.21–1.97, p=0.001), with the effect amplified by tobacco exposure (OR=2.23 with smoking, OR=2.40 with tobacco chewing). This is mechanistically expected: the urothelium continuously excretes carcinogens from tobacco and other environmental sources, making efficient NER especially critical for this tissue.

In contrast, [lung cancer meta-analysis | PLOS One 2014 — 2,605 patients, 5 studies] found no significant association (AlaVal/ValVal OR=1.054, CI 0.95–1.17), suggesting that rs2228000 risk is tissue-specific rather than uniform across all carcinogen-exposed organs. Digestive system cancers show a more complex picture: pooled analysis of gastric and esophageal cancer studies in mostly Chinese populations found a modest protective effect of the T allele in the dominant model (OR=0.84, CI 0.76–0.94), possibly reflecting population-specific effects or confounding.

In a South Indian case-control study of chronic myeloid leukemia⁶⁶ South Indian case-control study of chronic myeloid leukemia
Dixit et al. Gene 2021 — 212 CML cases and 212 controls, the Val allele showed markedly elevated CML susceptibility (CT: OR=1.92, CI 1.21–3.06; TT: OR=2.84, CI 1.22–6.71) and correlated with disease progression and splenomegaly. This is a small, single-population study and should be interpreted cautiously, but it extends the signal for Ala499Val beyond solid tumors.

The actionable landscape for rs2228000 parallels the companion variant rs2228001 but with evidence concentrated specifically in bladder and breast cancer rather than the broader multi-cancer associations of Lys939Gln. For Val/Val homozygotes — roughly 6% of the global population, with higher prevalence in East Asians (~12%) — the bladder cancer risk elevation is clinically meaningful (OR=1.68), particularly when tobacco exposure is present.

The most direct intervention is reducing carcinogen input: tobacco abstinence removes the major modifiable source of urothelial carcinogen load, and the gene-environment interaction documented in the bladder cancer data (OR up to 2.40 with tobacco chewing) makes this more impactful for Val carriers than for the general population.

For breast cancer risk, the Val/Val association (OR=1.33) is modest in absolute terms and does not approach the penetrance of BRCA1/2 variants, but it is consistent across studies and can be incorporated into personalized screening timing discussions alongside other risk factors.

XPC operates in sequence with XPA (rs1800975) and ERCC2/XPD (rs13181): XPC identifies DNA damage, XPA verifies the lesion, and XPD unwinds the DNA duplex to allow excision. Carriers of risk alleles at rs2228000 (damage recognition) and rs1800975 (damage verification) may have compounded NER deficiency, with each step of the cascade functioning below optimal efficiency simultaneously.

The companion variant rs2228001 (Lys939Gln) maps to XPC's TFIIH-interaction domain, a functionally distinct region from the codon-499 DNA-binding region. Individuals carrying risk alleles at both positions may have the most compromised XPC function, as both the initial damage binding step and the subsequent TFIIH recruitment step are impaired. Haplotype analyses including both rs2228000 and rs2228001 show stronger cancer risk prediction than either variant alone in several Asian population studies.